Share
5 min read
researchEvidence-based

The woman who defied the Alzheimer's Disease odds (and what it means for APOE4 carriers)

3 Alzheimer's-Blocking Genes Reveal What APOE4 Carriers Should Do Differently

T
· Reviewed by Dr. Kevin Tran, PharmD

Key takeaways · TL;DR

A Colombian woman carrying the PSEN1 early-onset Alzheimer mutation should have shown symptoms at 44 but stayed sharp until 73, thanks to two copies of the APOE Christchurch variant. Her brain was full of amyloid plaques, yet tau damage never cascaded. This finding, alongside APOE2 and Jacksonville variant research, points APOE4 carriers toward three distinct protective pathways to target.

Definition

Rare protective APOE mutation (R136S) that blocks the tau cascade downstream of amyloid plaques, delaying Alzheimer symptoms.

Definition

Protective APOE mutation that improves lipid transport and prevents APOE protein aggregation in the brain.

Three Protective APOE Variants and Their Mechanisms

VariantPrimary MechanismAPOE4 Carrier Target
APOE2Prevents amyloid accumulationSleep, glymphatic clearance, waste removal
ChristchurchBlocks tau cascade after amyloid formsNeuroinflammation control, cold exposure, polyphenols
Jacksonville (V236E)Improves lipid transport and APOE stabilityDHA, metabolic health, lipid optimization

Phoenix friends,

Quick story that's been in my head:
Woman in Colombia. Has the mutation for early-onset Alzheimer's (PSEN1). Should have developed symptoms at 44.

Instead? Symptoms at 73.

Her secret: Two copies of the Christchurch variant.

But here's what's wild: her brain was FULL of plaques.

The variant didn't prevent them. It prevented what came after.
It blocked the tau cascade that actually destroys neurons.

This completely changes how we think about the amyloid-tau relationship.
Then I dug deeper in that conference and they covered the mechanism of action of two other protective variants:

  • APOE2: Prevents amyloid from ever accumulating (like having a super-efficient garbage truck)

  • Jacksonville (V236E): Improves lipid transport and prevents APOE aggregation (fixes the brain's delivery system)

You are probably thinking: “Yeah Kevin, but I don’t have those protective genes. I carry ApoE4 and good for them, but what does it mean for me?”

Researchers aren’t just studying these protective genes out of curiosity. They want to understand how they work so they can mimic their effects and eventually develop new therapies.

Why this matters: Each variant works on a different part of the protein and targets a different disease mechanism. They're scattered across different protein domains—some affect receptor binding (N-terminal), others affect lipid binding (C-terminal). It's like having different tools that each fix a different part of the problem.

So what am I actually doing with this?
Still figuring it out, to be honest. But here's where my head is:

  1. For amyloid: Really doubling down on sleep quality and anything that enhances glymphatic clearance. If APOE2 keeps the brain "clean," maybe we can mimic that with better waste removal.

  2. For tau: This has me rethinking inflammation. The Christchurch variant seems to change how cells respond to stress. Cold exposure? Specific polyphenols? Still researching.

  3. For lipid transport: DHA supplementation makes even more sense. So does everything around metabolic health.

The real question: Should we be targeting all three pathways instead of focusing over just one?

I made a video breaking down all three mechanisms

-Kevin

P.S. Should mention this isn't medical advice. I’m just sharing research I'm personally tracking for obvious reasons.

Filed under
researchcognitionsupplementssleep

Discussion

Join the conversation

Your email will never be published. Be respectful and constructive.

FAQ

Frequently asked questions.

Who is the woman who defied the Alzheimer odds?
A Colombian woman carried the PSEN1 early-onset Alzheimer mutation, which typically causes symptoms around age 44. Instead, her cognitive symptoms did not begin until age 73. Researchers discovered she had two copies of the APOE Christchurch variant. Remarkably, her brain was full of amyloid plaques, yet she did not develop the expected tau cascade and neurodegeneration. Her case reframes how scientists think about the amyloid-tau relationship and what protects some brains from decline.
What is the Christchurch variant and how does it protect against Alzheimer?
The Christchurch variant is a rare mutation in the APOE gene (R136S). Unlike APOE2, which reduces amyloid accumulation, Christchurch does not prevent plaques from forming. Instead, it blocks the downstream tau cascade that actually destroys neurons. This suggests tau pathology, not amyloid alone, may be the more critical therapeutic target. The Colombian case shows tau disruption can delay Alzheimer symptoms by nearly three decades even when amyloid is abundant.
What is the Jacksonville variant and how does it differ from Christchurch?
The Jacksonville variant (V236E) is another protective APOE mutation that improves lipid transport and prevents APOE protein aggregation. It fixes the brain lipid delivery system rather than blocking tau or amyloid directly. Each protective variant acts on a different disease mechanism: APOE2 prevents amyloid accumulation, Christchurch blocks tau cascade, and Jacksonville improves lipid handling. Together they map three distinct intervention targets for APOE4 carriers.
What can APOE4 carriers do to mimic these protective effects?
Target all three pathways. For amyloid (APOE2-like protection): double down on sleep quality and glymphatic clearance to help the brain remove waste. For tau (Christchurch-like protection): focus on lowering neuroinflammation, consider cold exposure and polyphenols that modulate cellular stress response. For lipid transport (Jacksonville-like protection): prioritize DHA supplementation and metabolic health. The question researchers raise is whether targeting all three simultaneously outperforms single-pathway approaches.
Does the Colombian case prove amyloid is not the primary driver of Alzheimer?
It strongly suggests tau, not amyloid, is the more immediate driver of neurodegeneration. The woman had extensive amyloid plaques yet remained asymptomatic for decades because the tau cascade was blocked. This complicates the amyloid-centric view of Alzheimer that has dominated drug development. It does not mean amyloid is irrelevant, but rather that stopping the amyloid-to-tau handoff may be where the biggest therapeutic gains live, reframing prevention for APOE4 carriers.
Keep reading

Related protocols.